Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 29 Nov 2006):
Free Full Text!
See links below

Augmented designs to assess immune response in vaccine trials.

Full Abstract

This article introduces methods for use in vaccine clinical trials to help determine whether the immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the HIV-specific immune response in placebo recipients would have been, had they been vaccinated, this immune response could be treated essentially like a baseline covariate and an interaction with treatment could be evaluated. Relatedly, the rate of infection by this baseline covariate could be compared between the two groups and a causative role of immune response would be supported if infection risk decreased with increasing HIV immune response only in the vaccine group. We introduce two methods for inferring this HIV-specific immune response. The first involves vaccinating everyone before baseline with an irrelevant vaccine, for example, rabies. Randomization ensures that the relationship between the immune responses to the rabies and HIV vaccines observed in the vaccine group is the same as what would have been seen in the placebo group. We infer a placebo volunteer's response to the HIV vaccine using their rabies response and a prediction model from the vaccine group. The second method entails vaccinating all uninfected placebo patients at the closeout of the trial with the HIV vaccine and recording immune response. We pretend this immune response at closeout is what they would have had at baseline. We can then infer what the distribution of immune response among placebo infecteds would have been. Such designs may help elucidate the role of immune response in preventing infections. More pointedly, they could be helpful in the decision to improve or abandon an HIV vaccine with mediocre performance in a phase III trial.

 

Author information

Author/s: Follmann, Dean (D);

Affiliation: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 6700B Rockledge Drive MSC 7609, Bethesda, Maryland 20892, USA. dfollmann(-atsign-)niaid.nih.gov

Grants: NIH0010147213 (Agency:PHS HHS)

Journal and publication information

Publication Type: Journal Article

Journal: Biometrics (Biometrics), published in United States. (Language: eng)

Reference: 2006-Dec; vol 62 (issue 4) : pp 1161-9

Dates: Created 2006/12/12; Completed 2007/03/07; Revised 2008/11/20;

PMID: 17156291, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: AIDS Vaccines (0) ; Vaccines (0)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

5/13/1994
12/3/2007
Higher Relevance Score (39)
Lower Relevance Score (23)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index